News und Analysen

Results from Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT) foreshadow good news for MedTech investors. Both companies outperformed on the top and bottom lines, driven by broad

After a stellar first half to the year, especially when compared to last year's bloodbath, the S&P 500 index has been trending down since August. Friday was its third big down day in a row, and by

Abbott Laboratories (NYSE: ABT) share price has trended lower for nearly 2 years, but that trend is over. The impact of COVID on sales and the post-COVID letdown were cause enough for the market

Walgreens Boots Alliance (NASDAQ: WBA) shares are down significantly over the past two years and may fall further. The company's turnaround efforts are slowly taking hold, and the impact of

Over the last several months, many sectors, industries, and the overall market have come under pressure and experienced significant outflows and waves of selling. 

During this period, over the

Over the last month, the overall market has experienced significant selling amid increased uncertainty. The S&P 500 ETF Trust (NYSE: SPY) has traded almost 5.5% lower in that period, and wherever

The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.40% in the past three months, and down 4.67% year-to-date. 

With the current sector-wide downturn, it’s not surprising that

What started out to be a promising third quarter for U.S. stocks turned into a dud. On the backs of artificial intelligence (AI) excitement, the S&P 500 stormed out of the gates in July only to

If you had to guess the largest S&P company outside of big tech stocks or Berkshire Hathaway Inc. (NYSE: BRK.B), would you guess a healthcare stock? 

Health insurer UnitedHealth Group Inc. (NYSE:

While the direction of the stock markets is unpredictable, the growth of the aging population is entirely predictable. Along with an aging population come additional healthcare, beauty and

It’s not often that you see a company whose main product comes with a price tag of over $2 million, but that’s the case with biotechs BioMarin Pharmaceutical (NASDAQ: BMRN) and Sarepta

If you want to get an isolated view of a constructive base taking shape in a strong stock, take a look at the Argenix SE (NASDAQ: ARGX) chart. 

The stock gapped up nearly 28% on July 17, after

If you’re looking for a sector that’s on sale, look to healthcare. The Health Care Select Sector SPDR Fund (NYSEARCA: XLV) is down 2.50% in the past month, lagging the S&P 500. 

The top

Pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) stock has been on a tear, trading up 57.7% year-to-date (YTD). The company is firing on all cylinders with its leading medications and a highly

The healthcare industry presents a fertile shopping ground for undervalued dividend stocks. S&P 500 components Pfizer Inc. (NYSE: PFE), Medtronic plc (NYSE: MDT) and Gilead Sciences Inc. (NASDAQ:

The market's fear indicator, the VIX index, is bobbing along at long-term lows and gives little indication of a looming correction, but investors should assume one is brewing. The index is down at

Understanding insider buying is crucial for savvy investors looking to make informed decisions in the stock market. Insider buying occurs when company insiders, such as executives or directors,

The second quarter of the 2023 earnings season has drawn to a close. There were many surprises in every sector. However, there were some standout surprises with upcoming catalysts to watch. These

Major pharmaceutical companies including Johnson & Johnson (NYSE: JNJ), Novartis AG (NYSE: NVS), Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. (NYSE: MRK), Eli Lilly & Co. (NYSE: LLY) and 

The market advanced following the August PCE price index report, but investors and traders should not discount the news. The PCE index remains cool relative to the peaks of the inflation scare,

Med tech has been on the skids for no fault of its own. It’s not the industry's fault that price action was driven to a frothy bubble by COVID-inspired trading outlooks or that the market has

3M (NYSE: MMM) is an interesting speculation on high-yield dividend growth and value, and now is an excellent time to take a bite. The company is navigating a difficult time with aplomb, and the